Eli Lilly & Co.’s (LLY) endocrine products portfolio includes Humalog, Humulin, and Forteo. The chart below shows revenues for several of the key drugs from the endocrine franchise since 1Q15.
Humalog includes various mealtime insulin products that help control blood sugar levels. Humalog reported growth of 17% to $708.4 million during 1Q17, compared to $606.3 million for 1Q16.
For the US market, the drug reported growth of 24% to $449.1 million in 1Q17 due to its strong sales. Also, there were changes in the estimates for rebates and discounts given in its 1Q16 revenues. As a result, the company reported lower Humalog sales in 1Q16. Outside the US market, the drug reported 6% growth to $259.4 million in 1Q17.
Forteo, a drug for the treatment of osteoporosis, reported 9% revenue growth to $347.5 million in 1Q17, compared to $318.6 million in 1Q16. This growth was driven by the drug’s strong performance in the US markets.
Humulin includes concentrated insulin products used to lower blood sugar levels in patients in cases where a higher dosage of insulin is required. The drug reported a 12% decline in revenues to $314.5 million during 1Q17, compared to $356.4 million during 1Q16. The revenues declined in the US market and in international markets.
To divest company-specific risk, investors can consider the PowerShares Dynamic Large Growth ETF (PWB), which holds 3.1% of its total assets in Eli Lilly. PWB also holds 3.1% of its total assets in Bristol-Myers Squibb (BMY), 3.2% in Celgene (CELG), and 3.4% in UnitedHealth Group (UNH).